TORONTO, June 12, 2026 — June 12, 2026 — Leads & Copy — Avicanna Inc., a biopharmaceutical company focused on plant-derived cannabinoid-based products, announced it has successfully closed a non-brokered private placement, raising approximately $600,002.1 in gross proceeds. The offering consisted of 4,000,014 units priced at $0.15 per unit.
Each unit comprises one common share and one-half of a common share purchase warrant. Each whole warrant grants the holder the right to purchase one common share at an exercise price of $0.20 per share, with this right valid until June 12, 2029, subject to potential adjustments.
The company plans to allocate the funds raised from this offering towards general working capital, administrative expenses, production and manufacturing costs, and research and clinical development initiatives.
The common shares and warrants issued in this offering, along with any shares acquired upon their exercise or conversion, are subject to a four-month hold period in accordance with Canadian securities laws. The closing of the offering is contingent on meeting certain conditions, including obtaining necessary approvals, such as that of the Toronto Stock Exchange.
Avicanna is a commercial-stage international biopharmaceutical company dedicated to advancing and commercializing cannabinoid-based products and formulations for global medical and pharmaceutical markets. The company operates with a robust scientific platform that encompasses research and development, clinical trials, and the successful commercialization of over thirty proprietary, evidence-based finished products. These efforts support four distinct commercial business pillars.
The Medical Cannabis formulary, RHO Phyto™, provides a wide array of proprietary products available in oral, sublingual, topical, and transdermal delivery methods. These products feature diverse cannabinoid ratios and are backed by ongoing education for patients and the medical community. RHO Phyto is an established brand in Canada, currently distributed nationwide across various channels, with plans for international expansion.
The MyMedi.ca medical cannabis care platform was established to enhance the patient journey and better meet the needs of medical cannabis users. Operated by Northern Green Canada Inc., MyMedi.ca offers a comprehensive product portfolio and bilingual, pharmacist-led patient support programs. It also provides specialized services for specific patient groups, such as veterans, and works with public and private payers for claims adjudication and reimbursement. The platform aims to equip the medical community with educational resources to integrate medical cannabis into healthcare practices.
Avicanna’s pharmaceutical pipeline is built upon its scientific platform, vertical integration, and real-world evidence. This has led to the development of proprietary, indication-specific cannabinoid-based candidates currently in various phases of clinical development. These candidates are designed to address unmet medical needs in areas including dermatology, chronic pain, and several neurological disorders.
The company’s Active pharmaceutical ingredients business, operating under Aureus Santa Marta™, is a majority-owned subsidiary, Santa Marta Golden Hemp SAS. This commercial-stage business focuses on supplying high-quality CBD, THC, and CBG in various forms to Avicanna’s international partners for use in the development and production of food, cosmetic, medical, and pharmaceutical products. SMGH also plays a crucial role in Avicanna’s supply chain, providing reliable input materials for its global consumer retail, medical cannabis, and pharmaceutical product lines.
Source: Avicanna Inc.
